Ignite Creation Date:
2025-12-24 @ 11:53 PM
Ignite Modification Date:
2026-05-29 @ 12:33 PM
Study NCT ID:
NCT05947851
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2023-07-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Sponsor:
Merck Sharp & Dohme LLC
Organization: